Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Atreca secured $125M; OncoResponse bags $40M; Kodiak Sciences’s IPO; Biodesy contemplates $20M

Atreca secured $125M; OncoResponse bags $40M; Kodiak Sciences’s IPO; Biodesy contemplates $20M

Sep 13, 2018

Atreca secured USD 125 Million when solid tumor trial comes into picture

California based company, Atreca has bagged USD 125 million to establish its R&D activities. As the company gears up, the series C round enters, to move its lead solid tumor drug into the clinic.  Atreca has set up its credentials through VC rounds that added USD 91 million to its funds and engrossed the backing of investors like GlaxoSmithKline and the Bill & Melinda Gates Foundation. GSK and the Gates Foundation commenced working with Atreca too.

OncoResponse bags USD 40 Million for cancer patient-sourced antibodies

OncoResponse has secured USD 40 million in second-round financing to develop drugs based on antibodies taken from cancer survivors. The cash will be designated to get five programs from antibody-mining R&D of OncoResponse that is presently concentrated on melanoma, non-small cell lung cancer, prostate cancer, gastric cancer and chronic myeloid leukemia, into human testing. The company bagged USD 9.5 million in its series A round in 2015.

Kodiak Sciences gets ready for USD 100 Million IPO to progress Age-related Macular Degeneration (AMD) drug

Kodiak Sciences, California-based company, has filed to set up USD100 million in its IPO that will bolster the phase 2 development of anti-VEGF drug for eye diseases. It is now being tried in multiple trials in age-related macular degeneration (AMD) and diabetic retinopathy. The treatment is injected squarely into the eyes. The company is targeting to progress this with its prime drug, KSI-301.

Biodesy contemplates USD 20 Million in VC funding

The molecule-monitoring company, Biodesy declared that it has brought in USD 20 million in venture capital and chosen a new CEO. The company has been developing high-throughput systems that identify structural shifts in proteins and other biological molecules in real time, gauging how shape changes can affect function, pathway regulation and responses to drugs and novel candidates.

Downloads

Article in PDF

Recent Articles
  1. AKT Inhibitors: A potential Cancer Immunotherapy Target
  2. AstraZeneca’s new Asthma Drug Aces Phase III trial
  3. Wiskott – Aldrich syndrome – a rare X-linked disorder
  4. Survodutide Phase II trial Shows Groundbreaking Results in Liver Disease; GSK Announces Positive ...
  5. Stada’s €5.3B; Pfizer takes 30 cents; GSK, Exscientia ink deal; Trillium hunts for partners; Clem...
pharma-news-for-boehringer-ingelheim-novartis-astellas-pfizer
Notizia - Recent Pharma, Healthcare and Biotech Happenings

Boehringer Ingelheim’s Diabetic Macular Ischemia Study; Novartis’ Mariana Oncology Acquisition; Astellas and Poseida Therapeutics Partnership; Prime Medicine’s PM359 IND; Pfizer’s TIVDAK FDA Approval

Pharma News for BeiGene, GSK, Sandoz, Travere
Notizia - Recent Pharma, Healthcare and Biotech Happenings

BeiGene’s BRUKINSA Gets FDA Accelerated Approval; GSK’s Positive Results in DREAMM-8 Phase III; Sandoz’s Denosumab Biosimilars FDA Approved; Terns Pharma’s TERN-701 Receives Orphan Drug Designation; Wegovy® Approved in US for Overweight Cardiovascular Risk; Travere Therapeutics Submits sNDA for FILSPARI IgAN Full Approval

Pharma News for GSK, Sanofi, Biogen, Artiva
Notizia - Recent Pharma, Healthcare and Biotech Happenings

Survodutide Phase II trial Shows Groundbreaking Results in Liver Disease; GSK Announces Positive Headline Results from EAGLE-1 Phase III Trial; Dupixent sBLA Accepted for FDA Priority Review; Biogen’s QALSODY Received Positive Opinion from CHMP; FDA Granted Orphan Drug Designation to Immune-Onc’s IO-202; Artiva Biotherapeutics’s AlloNK® in Lupus Nephritis

Age-related macular degeneration
Atreca
Biodesy
diabetic retinopathy
GlaxoSmithKline
IPO
Kodiak Sciences
KSI-301
OncoResponse
second-round financing
the Bill Melinda Gates Foundation
venture capital
loader